Details of the Drug | DrugMAP

General Information of Drug (ID: DMXRJ1N)

Drug Name

PRAME antigen-specific cancer immunotherapeutic

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Phase 2	[1]
Melanoma	2C30	Phase 1	[2]
Metastatic melanoma	2E2Z	Phase 1	[2]
------------------------------------------------------------------------------------

Cross-matching ID

TTD ID: D00AHT

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	ClinicalTrials.gov (NCT01853878) A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of GlaxoSmithKline.